 |
|
An Evaluation of Prostate-Specific Antigen as a Screening Test for Prostate Cancer
Victoria J. Dorr, MD;
Stephen K. Williamson, MD;
Ronald L. Stephens, MD
Arch Intern Med. 1993;153(22):2529-2537.
Abstract
Prostate cancer is the second leading cause of cancer death in men. Recently, there has been increased interest in the use of prostate-specific antigen (PSA) as a screening test for prostate cancer. The PSA test offers the benefit of a reproducible, objective value that is independent of the examiner's skill; however, it does not seem to be effective alone as a screening test for prostate cancer. Additionally, the efficacy of treatment for prostate cancer with radiation therapy or radical prostatectomy remains to be demonstrated. Thus, further studies demonstrating an improved mortality in prostate cancer with PSA screening need to be performed before universal screening with PSA can be recommended. Meanwhile, education of the patient regarding the risks, benefits, and costs of PSA screening and subsequent treatment should be addressed before performing a PSA test.
(Arch Intern Med. 1993;153:2529-2537)
Author Affiliations
From the Division of Oncology, Department of Medicine, University of Kansas Medical Center, Kansas City.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
The Impact of Informed Consent on Patient Interest in Prostate-Specific Antigen Screening
Wolf et al.
Arch Intern Med 1996;156:1333-1336.
ABSTRACT
Use of Prostate-Specific Antigen for Prostate Cancer Screening in Primary Care Practice
Williams et al.
Arch Fam Med 1995;4:311-315.
ABSTRACT
Prostate Cancer Screening: What Family Physicians Believe Is Best
Hicks et al.
Arch Fam Med 1995;4:317-322.
ABSTRACT
Screening for Prostate Cancer: A Decision Analytic View
Krahn et al.
JAMA 1994;272:773-780.
ABSTRACT
|
